Beijing Tiantan Biological Products Co., Ltd.

Shanghai Stock Exchange 600161.SS

Beijing Tiantan Biological Products Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 50.76%

Beijing Tiantan Biological Products Co., Ltd. Gross Profit Margin is 50.76% for the year ending December 31, 2023, a 3.44% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Beijing Tiantan Biological Products Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 49.08%, a 3.25% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 47.53%, a -4.32% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 49.67%, a -0.36% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 49.85%, a 5.67% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 600161.SS

Beijing Tiantan Biological Products Co., Ltd.

CEO	Mr. Dao Xing Fu
IPO Date	June 16, 1998
Location	China
Headquarters	No. 2 Courtyard
Employees	4,858
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.

Key trends

Past 5 years